Member access

4-Traders Homepage  >  Shares  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

ASTELLAS PHARMA INC (4503)

10
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

09/08/2011 | 10:10pm US/Eastern

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

React to this article
Latest news on ASTELLAS PHARMA INC
05/27 ASTELLAS PHARMA : And Medivation Announce New Enzalutamide Data Presented At The..
05/26DJNew Push Ties Cost of Drugs to How Well They Work
05/26 ASTELLAS PHARMA : Strategic Plan 2015-2017 (pdf 392KB) (pdf 392 KB)
05/26 ASTELLAS PHARMA : Strategic Plan 2015-2017 (pdf 392 KB)
05/26 ASTELLAS PHARMA : Announces Acquisition of Own Shares (pdf 62KB)
05/26 ASTELLAS PHARMA : Announcement of Approval of Additional Indication for the TNF-..
05/26 ASTELLAS PHARMA : Receives Approval for a Supplemental New Drug Application for ..
05/26 ASTELLAS PHARMA : Cyclenium Pharma Updates on Drug Discovery Collaboration Agree..
05/22 ASTELLAS PHARMA : Releases Data from BESIDE Trial in Plenary Session at AUA 2015
05/22 ASTELLAS PHARMA : and Medivation Release New Enzalutamide Data at the 2015 Ameri..
Advertisement
Chart
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Income Statement Evolution
More Financials